356 Index Name Paper ref. Name Paper ref. Nichols, CG FC12.4.3 Nichter, M Wed 172, Wed 172 Nicolau, S Tue 042 Nicoletti, F Wed 400 Nicolucci, A W18.2 Nicotra, F Tue 093 Nie, L-Y Mon 470 Nie, YL Mon 032 Nieber, K Wed 417 Nieber, K Thu 317, Tue 238 Nielsen, C FC14.3.5 Nielsen, E W29.3, Thu 222 Nielsen, HB Mon 050 Nielsen, J Tue 303 Nielsen, LP Tue 356, Tue 357, Tue 358 Nielsen, NM Tue 038, Wed 433 Nielsen, S FC02.2.2 Niemi, M Tue 062, Tue 330, Tue 316, Thu 284 Nieminen, R FC09.1.5, FC09.2.5, FC16.3.4, W21.5, Mon 302, Tue 235, Tue 239, Tue 278, Tue 283, Thu 223, Niesters, M W12.4 Nieto, MA Mon 374 Niida, S Thu 286 Niihara, H Wed 083 Niikura, K Thu 188 Nijkamp, F FC09.5.2 Niki, T Tue 140 Nikitina, T Wed 347 Nikolic, D W34.3 Nikolic, V Thu 070, Nikolic-Kokic, A Wed 387, Thu 318 Nilsson Remahl, I Tue 308 Nin, N Thu 235 Nishibori, M Tue 272, Mon 035, Mon 329, Thu 275 Nishida, M Thu 109 Nishida, Y Mon 272 Nishihara, K Tue 225 Nishikawa, H Tue 263 Nishimaki-Mogami, T Thu 250 Nishimoto, A W01.2.3, Mon 399, Thu 046 Nishimura, Y Tue 320, Thu 319, Thu 343 Nishino, M W23.4, Tue 473 Nishio, H Tue 467 Nishioka, Y Wed 278 Nishiuchi, A Thu 320 Nishiwaki, M Mon 307 Nishiya, T Mon 399 Niu, J Tue 371, Tue 425 Niwa, M Mon 112, Thu 402 Nobakht, M Mon 188 Nobe, H Thu 224 Nobe, K Tue 201, Wed 256, Thu 117, Thu 224 Nobuoka, Y Tue 486 Noches, V Wed 169 Noda, M Wed 141 Noda, Y Thu 402 Noe, CR W24.2 Noedl, H Tue 090 Noehr-Jensen, L FC13.5.5 Noguchi, A Tue 136 Noguchi, K Thu 344 Noguchi, N Tue 153 Noguera, M-A Thu 050 Nolasco-Velazquez, XE Tue 025 Noll, G FC16.1.2 Nomura, F Tue 126, FC13.2.5 Nonaka, K Wed 371 Nor Aripin, KNB Thu 007 Norel, X Thu 266 Nørgaard, ML FC04.2.4 Nørgaard-Strandfelt, K FC02.3.6 Norman, E Thu 008 Norstedt, G Tue 391, Tue 392 Nosalova, G Mon 293 Nosjean, O Wed 072 Nossent, AY FC06.2.5 Nossent, Y Wed 070 Nouailhetas, VLA Thu 351, Thu 352 Nour El-Din, NA Tue 264 Novaes, LC Thu 321 Novaes, MR Tue 008, Thu 323, Thu 322, Thu 321 Novakova, E Mon 293 Novakova, M Thu 039 Novakovic, A Wed 103, Thu 324 Noveck, R Tue 228, Wed 122, Wed 121, Wed 120 Novella, S Thu 225 Novensa, L YI.03 Novensa, L Thu 225 Novio, S Thu 325 Novosad, J Tue 222, Tue 421, Tue 240 Novosadova, M Tue 240 Novotny, L Tue 343, Tue 074 Nowaczyk, M Mon 262 Ntaios, G Mon 143 Ntale, M FC01.4.5 Nürnberg, B Wed 022 Nugroho, AW Tue 009 Nukui, K Mon 405 Nulman, I Thu 009 Nunes, FPB Wed 333, Wed 334 Nunes, S Wed 214 Nuñez, MJ Wed 152 Nuñez-Iglesias, MJ Thu 325 Nunn, A J FC10.3.3 Nurfadhlina, M Thu 181 Nuriyev, M Tue 245 Nurullina, DV Thu 096 Nutt, D J FC17.4.4 Nuutinen, S FC14.3.6 Nyegaard, M FC13.3.6 Nygaard Jørgensen, T Mon 067 Nygaard, EB FC05.3.5 Nygaard, R Thu 036 Oates, J FC05.3.6 Obando, EP Mon 480 Obara, K Thu 226 Obili, N Tue 133 O'Brien, S Tue 364 Obua, C FC01.4.5 Ocampo-López, JO Tue 195 Ochi, A Mon 335
Name Paper ref. Name Paper ref. Ochiai, T Thu 430 Ochiai, W Mon 177, Mon 182 Ochodnicky, P FC05.4.5, Mon 219, Thu 097, Mon 221 Odar-Cederlöf, I Tue 308, W35.4 Odenholt, I W29.2 Odeon, MM Mon 040 Odlind, V FC10.1.4 O'Donnell, P Thu 402 Odoriz, B Mon 280 Oduola, MJ YI.09 Offermanns, S FC11.5.3, Wed 056 Offiah, NV Thu 326 Offringa, M W36.1, W36.3 Ofori-Adjei, D W36.1, W36.5 Ogawa, R Tue 486 Ogawa, Y Tue 470 Oger, S Mon 233, Mon 232 Ogihara, M Tue 390 Ogita, K Thu 099, Tue 376, Mon 461, Wed 083, Tue 375 Oguchi, K Wed 128, Wed 372, Tue 443 Ogundele, SO Tue 100 Ogunleye, OO Tue 100 Ogwal-Okeng, J Tue 005, Wed 136 Oh, D-H Wed 142, Tue 044, Tue 043, Wed 143 Oh, J-Y Thu 385 O'Halloran, A Tue 364 O'Hara, G Wed 123 Ohashi, K Tue 144 Ohata, H Wed 256 Ohhara, M Tue 168 Ohi, K Mon 182 Ohkubo, S Wed 078 Ohkubo, T Tue 147 Ohlstein, E Tue 479 Ohmoto, Y Thu 103 Ohnishi, K Tue 484, Tue 491 Ohta, H Thu 430 Ohta, R Tue 459 Ohtake, S Tue 477 Ohura, K Tue 266 Ohya, S Wed 107, Thu 102, Thu 107 Oida, Y Thu 406 Oikawa, A Thu 414 Oikonen, V Mon 256 Oishi, K Tue 470 Oishi, R Mon 093, Thu 109 Oiso, S Tue 167 Ojala, Y FC14.3.6 Ojoo, A FC10.3.1 Okada, M Thu 108 Okamoto, H Tue 153 Okamoto, S Mon 459 Okamura, C Wed 305 Okamura, M Mon 329 Okamura, N FC17.5.6 Okamura, T Wed 200 Okaniwa, T Mon 177 Okazaki, M Wed 266, Thu 227 Okechukwu, P Thu 327 Oki, K Mon 402 Okubo, K Tue 077 Okuda, A Wed 373 Okuda, T Tue 373 Okulicz-Kozaryn, I Thu 174 Okuno, T Tue 443 Okuno, Y Tue 468 Okuyama, C Tue 241 Okuyama, H Tue 147 Okwara, V Mon 017 Okyar, A Tue 245, Tue 142 Ola, R Mon 215 Olazabal, EV Mon 038 Olde, B Thu 074, Thu 047, Wed 052, Wed 062 Oldenburger, A Tue 242 Olesen, J PL13, Thu 106, Mon 099 Olesen, S-P FC06.1.4, Wed 282 Olinda, T Wed 318, Mon 299, Wed 319 Oliveira, A C Wed 144 Oliveira, F Mon 097 Oliveira, JL FC04.4.6 Oliveira, L Thu 025 Oliveira, MFSC YI.08 Oliveira, PRB Wed 341, Wed 340 Oliveira, R Mon 298 Oliveira, SHP Tue 243 Oliveiros, B Mon 350 Oliver, DW Mon 442 Oliver, DW Mon 412 Oliver, E Tue 165, Thu 048, Tue 163 Oliver, V Tue 202 Oliveros, I Tue 362 Olivier, E Thu 332 Olivier, NB Wed 156 Olli, A Tue 433 Olmez, E Wed 357 Oloro, J Tue 209 Olowofela, A Tue 010 Olsen, JV Wed 036 Olukman, M Thu 228 Olurishe, T Tue 011, Wed 145 O'Mahony, B Thu 177 Omar, MH Thu 328 Omara, EA Tue 451 Ombrato, R Thu 433 Omic, S Tue 437 Omidi, Y Mon 044, Onaivi, E Thu 176 Onaran, O Thu 049 Onat, F Mon 418 Oneda, B Mon 160 Ong, KL Mon 271, Mon 159 Oniki, H Tue 162 Onlamul, W Thu 361 Ono, K Tue 430 Onoe, H Tue 244 Onoue, S Tue 216 Ooga, K Thu 103 Opie, L FC06.3.1 Oppenheim, C Mon 191 Or, PMY Thu 389 Orallo, F FC16.2.5, Wed 359 Oram, D FC05.3.6 Oransay, K Tue 449, Tue 366 Ordyan, N FC17.1.6 Index 357
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295:
W29 New horizons in therapeutic dru
- Page 296 and 297:
FC14 Addiction and doping: Neurobio
- Page 298 and 299:
FC15 Endothelium in health and dise
- Page 300 and 301:
FC15 Endothelium in health and dise
- Page 302 and 303:
FC15 Endothelium in health and dise
- Page 304 and 305:
FC16 Natural products: Past and fut
- Page 306 and 307:
FC16 Natural products: Past and fut
- Page 308 and 309: FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor